Compass Therapeutics stock plunges 61% after cancer drug trial data flaws

10 articles · Updated · Barron's · Apr 27

Shares fell to $1.97, their largest single-day drop, after trial design issues left overall survival data for tovecimig statistically insignificant.
Although the drug delayed disease progression in biliary tract cancer, patient crossover confounded survival results, intensifying pressure on Compass, which has no marketed products.
Compass still plans to seek FDA approval for tovecimig, originally developed by ABL Bio, despite the setback and recent orphan drug designation for the treatment.

A drug cut cancer progression by 56%, so why did the company's stock plummet 23%?

Why are investors ignoring a huge survival benefit seen in patients who switched treatments?

How will the FDA's new AI inspection tools affect the approval path for Compass's drug?

Did an ethical trial design unintentionally mask a life-saving cancer drug's true potential?

Is the 'gold standard' for approving cancer drugs becoming an outdated and impossible goal?